Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CERS

Cerus Corp

Feb 13 • 04:00PM ET

2.24

+0.07 3.23 %

Healthcare • Medical Devices • USA • NASD

Peers: QDEL BIO HCSG AEMD ARWR AXDX MMSI FATE INSP XERS

| Held by: ARKK ARKG VTI IWM VXF IWO FESM SCHA VTWO SMLF

Index	RUT	P/E	-	EPS (ttm)	-0.08	Insider Own	4.74%	Shs Outstand	192.04M	Perf Week	1.82%
Market Cap	430.28M	Forward P/E	-	EPS next Y	-0.04	Insider Trans	-0.33%	Shs Float	182.98M	Perf Month	-18.25%
Enterprise Value	450.70M	PEG	-	EPS next Q	-0.01	Inst Own	73.20%	Short Float	3.68%	Perf Quarter	35.76%
Income	-15.96M	P/S	2.16	EPS this Y	28.36%	Inst Trans	-0.35%	Short Ratio	4.71	Perf Half Y	76.38%
Sales	199.19M	P/B	7.00	EPS next Y	50.48%	ROA	-7.89%	Short Interest	6.73M	Perf YTD	8.74%
Book/sh	0.32	P/C	5.48	EPS next 5Y	-	ROE	-27.78%	52W High	2.95 -24.20%	Perf Year	24.44%
Cash/sh	0.41	P/FCF	2531.06	EPS past 3/5Y	29.07% 25.97%	ROIC	-13.22%	52W Low	1.12 100.00%	Perf 3Y	-25.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	11.27% 13.96%	Gross Margin	55.19%	Volatility	6.33% 5.90%	Perf 5Y	-70.33%
Dividend TTM	-	EV/Sales	2.26	EPS Y/Y TTM	21.28%	Oper. Margin	-18.21%	ATR (14)	0.14	Perf 10Y	-56.16%
Dividend Ex-Date	-	Quick Ratio	1.29	Sales Y/Y TTM	13.03%	Profit Margin	-8.01%	RSI (14)	48.77	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.89	EPS Q/Q	99.37%	SMA20	-4.56%	Beta	1.54	Target Price	4.67
Payout	-	Debt/Eq	1.60	Sales Q/Q	14.52%	SMA50	1.15%	Rel Volume	0.74	Prev Close	2.17
Employees	281	LT Debt/Eq	0.97	Earnings	Nov 06 AMC	SMA200	38.68%	Avg Volume	1.43M	Price	2.24
IPO	Jan 31, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 4.18%	Trades		Volume	1,055,396	Change	3.23%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	Craig Hallum	Buy	$5
Jan-20-23	Downgrade	BTIG Research	Buy → Neutral
Jan-17-23	Downgrade	Stephens	Overweight → Equal-Weight	$3.75
Oct-08-20	Resumed	BTIG Research	Buy	$9
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$9
Feb-26-20	Initiated	BTIG Research	Buy	$7
Nov-13-19	Upgrade	BTIG Research	Neutral → Buy	$7
Aug-28-19	Initiated	Stifel	Buy
Aug-23-19	Resumed	Stephens	Overweight
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Dec-08-17	Resumed	BTIG Research	Neutral
Jul-07-16	Resumed	Cantor Fitzgerald	Buy	$9
Dec-17-15	Downgrade	Wedbush	Outperform → Neutral
May-02-14	Reiterated	MLV & Co	Buy	$8.50 → $6
Apr-24-13	Reiterated	Cantor Fitzgerald	Buy	$5.50 → $6
Mar-15-13	Reiterated	MLV & Co	Buy	$7.50 → $8.50
Apr-17-12	Initiated	Cantor Fitzgerald	Buy	$5.50
Feb-29-12	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $6
Nov-10-11	Reiterated	MLV & Co	Buy	$4 → $5
Jun-03-11	Initiated	Wedbush	Outperform	$4

Show Previous Ratings

Jan-22-26 07:30AM	DRK Blood Donation Service Baden-Wurttemberg - Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT Blood System in Routine Clinical Practice (Business Wire)
Jan-11-26 04:00PM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook (Business Wire)
Dec-27-25 07:43AM	TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS) (Insider Monkey)
Dec-10-25 04:15PM	Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America (Business Wire) +13.76%
Nov-07-25 12:01AM	Cerus Corp (CERS) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Shifts Amid ... (GuruFocus.com) +21.28%
05:07PM	Loading…
Nov-06-25 05:07PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance (Business Wire)
Oct-21-25 08:30AM	Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting (Business Wire)
Oct-16-25 04:00PM	Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Aug-25-25 09:00AM	The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions (Business Wire)
Aug-21-25 08:30AM	Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-05-25 05:04PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Cerus Corporation Announces Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 10:06AM	Cerus Corp (CERS) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-22-25 04:15PM	Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
08:30AM	Loading…
Jul-21-25 08:30AM	Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury (Business Wire)
Jul-02-25 08:30AM	Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update (Business Wire) +5.41%
Jun-13-25 04:01PM	Cerus Corporation Celebrates World Blood Donor Day 2025 (Business Wire) +6.82%
Jun-03-25 04:30PM	Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.09%
May-29-25 08:30AM	Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan (Business Wire)
May-28-25 08:30AM	Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 Next-Generation INTERCEPT Illumination Device (Business Wire)
May-01-25 08:26PM	Cerus Corporation (CERS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:05PM	Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2025 Financial Results (Business Wire)
Apr-17-25 08:30AM	Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 (Business Wire)
Mar-06-25 11:44AM	Cerus secures CE mark approval for LED-based illumination device (Medical Device Network)
Mar-05-25 01:00PM	Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) (Business Wire)
Feb-21-25 02:14AM	Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow (GuruFocus.com) -5.17%
Feb-20-25 04:20PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results (Business Wire)
09:27AM	What To Expect From Cerus Corp (CERS) Q4 2024 Earnings (GuruFocus.com)
Feb-19-25 04:00PM	Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-07-25 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 (Business Wire)
Jan-13-25 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update (Business Wire) +5.70%
Nov-13-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Oct-31-24 02:11PM	Q3 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) -8.72%
05:01AM	Cerus Corp (CERS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-30-24 05:10PM	Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2024 Financial Results (Business Wire)
Oct-29-24 09:16AM	Cerus Corp (CERS) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-18-24 08:30AM	Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024 (Business Wire)
08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting (Business Wire)
08:25AM	Cerus price target lowered to $3 from $6 at Stifel (TipRanks)
Oct-16-24 04:00PM	Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe (Business Wire) -9.44%
Oct-09-24 03:49PM	Cerus Corp (CERS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive EBITDA (GuruFocus.com) +8.72%
Sep-06-24 01:47AM	Insider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS) (GuruFocus.com)
Aug-01-24 05:10PM	Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.73% +14.95%
04:07PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range (Business Wire)
Jul-18-24 08:30AM	Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire) -6.36%
Jul-02-24 04:00PM	Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors (Business Wire)
Jun-21-24 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion (Business Wire)
Jun-14-24 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2024 (Business Wire)
May-22-24 08:30AM	Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference (Business Wire)
May-03-24 10:40AM	Cerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call Transcript (Insider Monkey) -7.95%
06:48AM	Q1 2024 Cerus Corp Earnings Call (Thomson Reuters StreetEvents)
03:58AM	Cerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-02-24 08:59PM	CERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:04PM	Cerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
04:04PM	Cerus: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces First Quarter 2024 Financial Results (Business Wire)
Apr-18-24 08:30AM	Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Mar-26-24 08:30AM	Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets Doubling Previous Shelf Life (Business Wire)
Mar-19-24 08:00AM	Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients (Business Wire) +9.68%
Mar-15-24 01:49AM	Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS) (GuruFocus.com)
01:48AM	Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS) (GuruFocus.com)
Mar-07-24 01:40PM	Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven (GuruFocus.com)
11:46AM	Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 06:23AM	Q4 2023 Cerus Corp Earnings Call (Thomson Reuters StreetEvents) +21.61%
Mar-05-24 09:53PM	CERS Stock Earnings: Cerus Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -6.13%
04:26PM	Cerus: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-20-24 08:30AM	Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-01-24 08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire) +8.84%
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-08-24 08:30AM	Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update (Business Wire) +5.61%
Nov-03-23 09:19AM	Cerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call Transcript (Insider Monkey) +8.81%
08:30AM	Cerus Corporation to Participate in Upcoming Investor Conferences (Business Wire)
Nov-02-23 06:43PM	Cerus Corp (CERS) Q3 2023 Earnings: Product Revenue Stable, Operating Expenses Decrease by 4% (GuruFocus.com) +15.22%
05:25PM	Cerus (CERS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Cerus: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-19-23 08:30AM	Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-10-23 08:30AM	Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting (Business Wire) +8.02%
Sep-27-23 08:30AM	Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer (Business Wire)
Sep-12-23 08:30AM	Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire)
Aug-02-23 05:15PM	Cerus (CERS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -17.98%
04:11PM	Cerus: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Cerus Corporation Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:36PM	Cerus (NASDAQ:CERS) investors are sitting on a loss of 60% if they invested three years ago (Simply Wall St.)
Jul-19-23 08:30AM	Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) +5.42%
Jul-03-23 05:13PM	12 Best NASDAQ Penny Stocks to Buy (Insider Monkey) -7.76%
Jun-15-23 08:30AM	Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress (Business Wire)
Jun-14-23 08:30AM	Cerus Corporation Celebrates World Blood Donor Day 2023 (Business Wire)
Jun-07-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jun-05-23 08:30AM	Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate (Business Wire)
May-30-23 07:16AM	With 72% institutional ownership, Cerus Corporation (NASDAQ:CERS) is a favorite amongst the big guns (Simply Wall St.) +5.70%

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jensen Chrystal	Chief Legal Officer	Nov 24 '25	Sale	1.70	55,000	93,500	728,294	Nov 26 04:07 PM
CHRYSTAL NIKOLE JENSEN	Officer	Nov 24 '25	Proposed Sale	1.70	55,000	93,500		Nov 24 05:17 PM
Gregory Dean A.	Director	Aug 25 '25	Buy	1.25	25,000	31,250	86,725	Aug 25 03:25 PM
Jensen Chrystal	Chief Legal Officer	Mar 14 '25	Sale	1.45	30,075	43,609	783,294	Mar 17 05:02 PM
Jensen Chrystal	Chief Legal Officer	Mar 13 '25	Sale	1.45	18,949	27,476	813,369	Mar 17 05:02 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 14 '25	Sale	1.45	46,004	66,706	1,431,326	Mar 17 05:01 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 13 '25	Sale	1.45	29,985	43,478	1,477,330	Mar 17 05:01 PM
Greenman William Mariner	President and CEO	Mar 14 '25	Sale	1.45	122,827	178,099	4,115,845	Mar 17 05:00 PM
Greenman William Mariner	President and CEO	Mar 13 '25	Sale	1.45	71,086	103,075	4,238,672	Mar 17 05:00 PM
Green Kevin Dennis	Chief Financial Officer	Mar 14 '25	Sale	1.45	36,740	53,273	875,867	Mar 17 04:56 PM
Green Kevin Dennis	Chief Financial Officer	Mar 13 '25	Sale	1.45	23,147	33,563	912,607	Mar 17 04:56 PM
Benjamin Richard J	Chief Medical Officer	Mar 14 '25	Sale	1.45	30,075	43,609	685,775	Mar 17 04:55 PM
Benjamin Richard J	Chief Medical Officer	Mar 13 '25	Sale	1.45	18,949	27,476	715,850	Mar 17 04:55 PM
Jensen Chrystal	Chief Legal Officer	Mar 07 '25	Sale	1.50	27,457	41,131	832,318	Mar 10 07:59 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 07 '25	Sale	1.50	33,999	50,931	1,507,315	Mar 10 07:56 PM
Greenman William Mariner	President and CEO	Mar 07 '25	Sale	1.50	60,984	91,354	4,309,758	Mar 10 07:55 PM
Green Kevin Dennis	Chief Financial Officer	Mar 07 '25	Sale	1.50	31,148	46,660	935,754	Mar 10 07:54 PM
Benjamin Richard J	Chief Medical Officer	Mar 07 '25	Sale	1.50	26,139	39,156	734,799	Mar 10 07:53 PM
Jensen Chrystal	Chief Legal Officer	Mar 04 '25	Sale	1.58	66,292	104,885	405,198	Mar 05 08:31 PM
Jayaraman Vivek K	Chief Operating Officer	Mar 04 '25	Sale	1.55	10,780	16,693	905,828	Mar 05 08:30 PM
Greenman William Mariner	President and CEO	Mar 04 '25	Sale	1.55	23,023	35,651	3,230,000	Mar 05 08:29 PM
Green Kevin Dennis	Chief Financial Officer	Mar 03 '25	Sale	1.58	60,656	95,673	493,862	Mar 05 08:27 PM
Green Kevin Dennis	Chief Financial Officer	Mar 04 '25	Sale	1.55	8,386	12,986	554,518	Mar 05 08:27 PM
Benjamin Richard J	Chief Medical Officer	Mar 03 '25	Sale	1.58	51,254	80,828	400,665	Mar 05 08:23 PM
Benjamin Richard J	Chief Medical Officer	Mar 04 '25	Sale	1.55	6,292	9,743	394,373	Mar 05 08:23 PM
Jensen Chrystal	Officer	Mar 04 '25	Proposed Sale	1.50	60,000	90,000		Mar 04 04:55 PM
RICHARD J BENJAMIN	Officer	Mar 03 '25	Proposed Sale	1.58	51,254	80,822		Mar 03 05:22 PM
KEVIN D GREEN	Officer	Mar 03 '25	Proposed Sale	1.58	60,656	95,646		Mar 03 04:56 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Feb 13 • 04:00PM ET

103.10

+1.09 1.07 %

Healthcare • Biotechnology • USA • NASD

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-0.86	Insider Own	12.13%	Shs Outstand	51.31M	Perf Week	2.62%
Market Cap	5.33B	Forward P/E	-	EPS next Y	-0.06	Insider Trans	-1.56%	Shs Float	45.41M	Perf Month	13.73%
Enterprise Value	5.27B	PEG	-	EPS next Q	0.04	Inst Own	99.18%	Short Float	17.17%	Perf Quarter	45.66%
Income	-41.42M	P/S	11.29	EPS this Y	86.38%	Inst Trans	6.77%	Short Ratio	10.24	Perf Half Y	59.03%
Sales	471.79M	P/B	18.12	EPS next Y	77.38%	ROA	-5.70%	Short Interest	7.80M	Perf YTD	30.52%
Book/sh	5.69	P/C	14.19	EPS next 5Y	-	ROE	-15.81%	52W High	105.74 -2.50%	Perf Year	103.35%
Cash/sh	7.27	P/FCF	120.23	EPS past 3/5Y	12.58% 4.14%	ROIC	-6.80%	52W Low	36.88 179.55%	Perf 3Y	337.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	79.85%	Volatility	2.83% 3.91%	Perf 5Y	390.95%
Dividend TTM	-	EV/Sales	11.17	EPS Y/Y TTM	58.63%	Oper. Margin	-8.86%	ATR (14)	3.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.16	Sales Y/Y TTM	53.66%	Profit Margin	-8.78%	RSI (14)	66.95	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	3.31	EPS Q/Q	117.12%	SMA20	3.72%	Beta	0.51	Target Price	114.70
Payout	-	Debt/Eq	1.09	Sales Q/Q	47.17%	SMA50	20.49%	Rel Volume	0.71	Prev Close	102.01
Employees	322	LT Debt/Eq	1.08	Earnings	Nov 04 AMC	SMA200	53.42%	Avg Volume	761.34K	Price	103.10
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	135.66% 1.93%	Trades		Volume	540,939	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Loading…
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
06:30AM	Loading…
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM

CERS

Cerus Corp

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience